1. Within your health trust how many patients are currently [within the past 6 months] being treated for head and neck cancer (Squamous cell carcinoma)?
2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?
A. Locally advanced
B. Recurrent and/or metastatic
Of the these patients please split by their current drug treatment;
Carboplatin (Only or in combination with 5-FU)
Cetuximab (Erbitux) and chemotherapy or radiotherapy
Cetuximab (Erbitux) Only
Cisplatin (Only or in combination with 5-FU)
Docetaxel (Taxotere), (Only or in combination with 5-FU)
Fluorouracil (5FU)
Radiotherapy Only
Other – Specify
3. Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so please could you provide details?
4. Within your health trust how many patients are currently [within the past 6 months] being treated for metastatic Colorectal Cancer?
Of those patients please split by their current drug treatment;

Bevacizumab
Cetuximab
Panitumumab
Aflibercept
Oxaliplatin
Irinotecan
5-Fluorouracil
Irinotecan with 5-fluorouracil (5FU) and folinic acid [FOLFIRI]
Oxaliplatin with 5-fluorouracil (5FU) and folinic acid [FOLFOX]
Capecitabine and oxalipatin (CAPOX / XELOX)
Capecitabine and irinitecan (CAPIRI)
Other – Specify

Download response Head and Neck Cancer (Squamous cell carcinoma) 270616